Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TETRACHEL vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Infections caused by susceptible strains of Rickettsiae,Mycoplasma pneumoniae infections,Psittacosis (ornithosis),Chlamydia trachomatis infections (e.g., uncomplicated urethral, endocervical, rectal),Brucellosis (in conjunction with streptomycin),Chancroid,Granuloma inguinale,Lymphogranuloma venereum,Relapsing fever,Bartonellosis,Plague,Tularemia,Acute intestinal amebiasis (adjunctive therapy),Severe acne,Propionibacterium acnes infections,Off-label: Helicobacter pylori eradication (as part of quadruple therapy)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Tetracycline is primarily metabolized in the liver via glucuronidation and undergoes enterohepatic circulation. Minor metabolism may involve microsomal enzymes.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
65% (primarily albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
1.3 L/kg (extensive tissue penetration, including bone and teeth).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 77-96% (decreased by food, dairy, antacids).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: 250 mg once daily. Cr Cl <30 m L/min: 125 mg once daily.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: 250 mg once daily. Child-Pugh C: 125 mg once daily.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Children ≥8 years: 5 mg/kg orally once daily (max 500 mg) for 28 days.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at low end of dosing range; monitor renal function and adjust dose based on Cr Cl.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Tetracycline can cause fetal harm when administered to a pregnant woman. Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). It should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Photosensitivity: exaggerated sunburn reaction; avoid direct sunlight and UV light.,Hepatotoxicity: may cause liver damage, especially in patients with renal impairment or receiving high doses.,Renal impairment: accumulation may occur; dosage adjustment required.,Superinfection: use of tetracycline may result in overgrowth of non-susceptible organisms, including fungi.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea has been reported.,Intracranial hypertension: bulging fontanelles in infants and benign intracranial hypertension in adults.,Tissue irritation: avoid extravasation; thrombophlebitis risk with IV administration.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to tetracyclines or any component of the formulation.,Pregnancy (especially second and third trimesters) and lactation.,Children under 8 years of age (except for specific infections like anthrax or where no alternative exists).,Severe hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid dairy products, calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum, as they reduce absorption. Iron supplements, bismuth subsalicylate, and zinc also chelate tetracyclines. Take tetracycline 1 hour before or 2 hours after meals. Avoid alcohol (hepatotoxicity risk).
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third trimesters (weeks 13 to 40) is associated with permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia in the child. Additionally, there is a risk of retarded skeletal growth and potentially reversible inhibition of bone growth. Use during the first trimester is generally discouraged unless no alternative therapy is available, as there may be a small risk of teratogenicity (e.g., neural tube defects, cardiovascular malformations) based on some observational studies, though evidence is conflicting.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Tetracycline is excreted into human milk, with milk-to-plasma ratio (M/P) approximately 0.5-0.8. Low levels of tetracycline are found in breast milk; however, due to potential for serious adverse reactions (e.g., permanent tooth discoloration and bone growth inhibition) in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profiles in lactation are preferred.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Due to physiological changes in pregnancy (increased plasma volume, increased renal clearance), tetracycline may achieve lower serum concentrations. However, specific dosing adjustment guidelines for tetracycline in pregnancy are not established. The drug is generally avoided in pregnancy, particularly after the first trimester. If use is necessary in the first trimester, standard dosing based on non-pregnant adults is typically used, but careful monitoring for efficacy and toxicity is recommended. No dose adjustment is recommended for hepatic or renal impairment in pregnancy as the drug is contraindicated in such conditions.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis. Avoid in children under 8 years and pregnant/breastfeeding women due to bone and tooth discoloration. Administer on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water to prevent esophagitis. Do not take with dairy, antacids, or iron supplements as they chelate and reduce absorption. Photosensitivity risk: advise sun avoidance and sunscreen use.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication on an empty stomach with a full glass of water.,Avoid dairy products, antacids, and iron supplements within 2 hours of taking this drug.,Use sunscreen and protective clothing to prevent severe sunburn.,Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction, severe headache, or vision changes immediately.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TETRACHEL vs ACTIQ, answered by our medical review team.
TETRACHEL is a Tetracycline Antibiotic that works by Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TETRACHEL and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TETRACHEL is: 500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TETRACHEL and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TETRACHEL is classified as Category C. Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third tri. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.